News Related to Rigel Pharmaceuticals

Related coverage linked through entity extraction aliases.

Pfizer Secures FDA Approvals for Two Cancer Drugs; Oncolytic Virus Pipeline Expands

Jun 01, 2026

The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.

Drug Discovery Patent Filings Span Protein Degradation, Ion Channels, and Emerging Targets

Feb 25, 2025

Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.